Xenon has developed isoform selective blockers of the sodium channels that are expressed in CNS neurons with the intent of developing them for therapeutic use, especially epilepsy. The primary goal of this research project is to determine the activity of compounds on CNS neurons. Until now, all characterization has been done with heterologously expressed channels. […]
Read More